Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2020 - 2026)

Monte Rosa Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$3.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 42.44% year-over-year to -$3.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 23.46% YoY), while the FY2025 annual figure was $7.9 million, up 87.67% from the prior year.
• Change in Accured Expenses was -$3.7 million for Q1 2026 at Monte Rosa Therapeutics, down from $8.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q4 2025 to a low of -$3.9 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $759529.4 across 5 years, with a median of $1.4 million in 2022.
• Biggest YoY gain for Change in Accured Expenses was 1590.65% in 2022; the steepest drop was 382.25% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2022, then plunged by 37.79% to $1.3 million in 2023, then jumped by 186.81% to $3.7 million in 2024, then surged by 136.27% to $8.7 million in 2025, then tumbled by 142.5% to -$3.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.7 million (Q1 2026), $8.7 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.